A Literature Review of Current Management of Patent Ductus Arteriosus in Neonates
Presented in National Medical Students Paediatric Conference (NMSPC) 2014, Brighton, UK
Daniel Crankshaw.
Lancaster Medical School, UK.
Background:Recent controversy has sparked interest into a potential new treatment for patent ductus arteriosus (PDA). Ten case series and two randomized controlled trials have now been carried out comparing paracetamol and ibuprofen. This review aims to investigate whether paracetamol could potentially be used as the new first line therapeutic option.

Methods: Literature review

Results: Eight out of the ten case series show that paracetamol was effective at closing the PDA in 71-100% of patients. Both randomized control trials were able to show that there was no statistically significant difference between the treatment regimes. One study also provided evidence that paracetamol causes fewer side effects than ibuprofen.

Conclusion: From the data available it does seem that paracetamol is a viable and potentially better therapeutic option for the treatment of PDA. This is due to it being as successful at closing PDAs with potentially fewer side effects. Further work should now be carried out to answer the limitations of the studies already available to. What is the optimum dose and treatment regime? What is the best route of administration and does treatment alter long-term outcomes?

Cite this article as:
Crankshaw D. A Literature Review of Current Management of Patent Ductus Arteriosus in Neonates. Pediatr Oncall J. 2014;11. doi: 10.7199/ped.oncall.2014.16S
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0